TextbookSurgeryCarotid Artery Disease

Carotid Artery Disease

Carotid artery disease is atherosclerotic stenosis of the carotid arteries, a major cause of ischaemic stroke and TIA. Carotid endarterectomy is indicated for symptomatic stenosis ≥50%.

MRCSPLAB 1UKMLA0 questions

Key Facts

Carotid stenosis accounts for ~20-30% of ischaemic strokes Carotid endarterectomy (CEA) should be performed within 14 days of symptoms for symptomatic stenosis ≥50% (NASCET criteria) — NICE CG68 NASCET criteria: Measure stenosis compared to normal distal ICA — 50-69% moderate, 70-99% severe NNT: ~6 for CEA in 70-99% symptomatic stenosis (ECST/NASCET trials); ~22 for 50-69% Asymptomatic stenosis ≥60%: Surgery debated; best medical therapy is increasingly favoured; consider surgery only in high-risk patients in specialist centres Duplex USS: First-line investigation — assesses degree of stenosis and plaque morphology Risk factors: Same as atherosclerosis — smoking, hypertension, diabetes, hyperlipidaemia, age Best medical therapy: Antiplatelet (clopidogrel 75mg), statin (atorvastatin 80mg), antihypertensive, smoking cessation

Overview

Key Facts

Carotid artery disease is a significant and treatable cause of stroke. Timely intervention with CEA in symptomatic patients reduces stroke risk substantially.

Epidemiology

~100,000 strokes/year in UK; ~20-30% caused by carotid disease. Asymptomatic carotid stenosis >50% found in ~5-10% of adults >65.

Aetiology

  • Atherosclerosis: ~95% of carotid disease
  • Plaque at carotid bifurcation: Low shear stress promotes plaque formation
  • Mechanism of stroke: Plaque rupture → thromboembolism to cerebral circulation (artery-to-artery embolism) — more common than haemodynamic compromise from stenosis

Pathophysiology

  • Atherosclerotic plaque most commonly at carotid bifurcation where ICA originates
  • Plaque vulnerability (lipid-rich core, thin fibrous cap, intraplaque haemorrhage) determines stroke risk
  • Emboli travel to MCA territory → cerebral ischaemia
  • CEA removes the plaque surgically → eliminates embolic source

Clinical Presentation

Symptomatic Carotid Disease

TIA (resolves within 24 hours):

  • Amaurosis fugax (transient monocular blindness — 'curtain descending over eye')
  • Hemiparesis, hemisensory loss (contralateral)
  • Dysphasia (dominant hemisphere)

Stroke (persistent deficit >24 hours):

  • Same territory as TIA but persistent
  • MCA territory most common

Asymptomatic

  • Bruit on auscultation over carotid bifurcation (not reliable — absent bruit doesn't exclude stenosis; bruit without stenosis possible)
  • Incidental finding on imaging

Red Flags

  • TIA or crescendo TIA — urgent assessment within 24 hours (ABCD2 score)
  • Acute stroke — thrombolysis/thrombectomy if eligible; CEA only after stabilisation

Differential Diagnosis

DiagnosisKey FeaturesInvestigation
Cardioembolic strokeAF, valvular disease, mural thrombusECG, echocardiography
Small vessel diseaseLacunar infarcts, hypertension, diabetesMRI brain
Aortic arch atheromaSource of embolism, often on TOETOE
Carotid dissectionYoung patient, neck pain, Horner's syndromeCT/MR angiography
Vertebrobasilar insufficiencyVertigo, diplopia, ataxia, drop attacksCT/MR angiography

Diagnosis / Investigation

Bedside

  • ABCD2 score: Risk stratify TIA (Age, BP, Clinical features, Duration, Diabetes)
  • Neurological examination: Document deficits

Bloods

  • FBC, U&Es, lipids, HbA1c, glucose: Cardiovascular risk
  • Coagulation: Pre-operative

Imaging

  • Carotid duplex USS: First-line — non-invasive; assesses stenosis degree and plaque morphology
  • CT angiography (CTA): Confirms stenosis degree; pre-operative planning
  • MR angiography (MRA): Alternative if CTA contraindicated
  • CT/MRI brain: Assess infarction territory
  • ECG/echocardiography: Exclude cardiac source

Stenosis Grading (NASCET)

  • Percentage = (1 − narrowest ICA diameter / normal distal ICA diameter) × 100

Management

Symptomatic Carotid Stenosis

70-99% stenosis:

  • CEA within 14 days of symptoms (NICE CG68) — NNT ~6 to prevent 1 stroke over 5 years
  • Delay beyond 14 days significantly reduces benefit

50-69% stenosis:

  • CEA offers modest benefit (NNT ~22) — consider based on patient factors
  • Greater benefit in men, older patients, cortical (vs retinal) events

<50% stenosis:

  • Best medical therapy only — CEA not beneficial

Near-occlusion (99%) or occlusion:

  • CEA not indicated for complete occlusion
  • Near-occlusion: Individual decision; benefit unclear

Asymptomatic Stenosis

  • Best medical therapy: First-line in most cases
    • Atorvastatin 80mg, clopidogrel 75mg, antihypertensive, smoking cessation
  • CEA: Consider only in specialist centres for patients with ≥60% stenosis AND additional high-risk features AND expected perioperative risk <3%
  • ACST-2 trial results suggest medical therapy may be comparable to surgery in asymptomatic patients

Carotid Artery Stenting (CAS)

  • Alternative to CEA in selected patients (high surgical risk, post-radiotherapy neck, recurrent stenosis)
  • Similar long-term outcomes to CEA but higher perioperative stroke risk (ICSS, CREST trials)

Referral Criteria

  • Symptomatic carotid stenosis ≥50% — urgent vascular surgery referral
  • TIA/stroke with carotid territory symptoms — rapid access TIA clinic/stroke team

Prognosis

  • CEA for 70-99% symptomatic: Reduces 5-year stroke risk from ~26% to ~9%
  • Perioperative stroke/death risk: ~2-3% in experienced centres (audit requirement)
  • Benefit diminishes with delay — maximal if done within 14 days; minimal after 12 weeks
  • Asymptomatic stenosis: Annual stroke risk ~1-2% with modern medical therapy (much lower than in original trials)
  • Long-term: Re-stenosis ~5-10% at 5 years after CEA; higher after CAS

Other Relevant Information

Key Trials in Carotid Surgery

TrialKey Finding
NASCETCEA beneficial for symptomatic 70-99% stenosis (NNT ~6)
ECSTConfirmed NASCET findings in European population
ACST-1CEA reduces stroke risk in asymptomatic ≥60% stenosis
ACST-2CEA vs CAS in asymptomatic — ongoing/recent results
ICSSCAS has higher perioperative stroke rate than CEA (symptomatic)
CRESTCEA and CAS similar long-term outcomes; CAS higher stroke, CEA higher MI